Cargando…

Dietary Strategies for Maintenance of Clinical Remission in Inflammatory Bowel Diseases: Are We There Yet?

The etiopathogenesis of Inflammatory bowel disease (IBD) is a result of a complex interaction between host immune response, the gut microbiome and environmental factors, such as diet. Although scientific advances, with the use of biological medications, have revolutionized IBD treatment, the challen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gkikas, Konstantinos, Gerasimidis, Konstantinos, Milling, Simon, Ijaz, Umer Z., Hansen, Richard, Russell, Richard K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400838/ https://www.ncbi.nlm.nih.gov/pubmed/32645980 http://dx.doi.org/10.3390/nu12072018

Ejemplares similares

Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn’s disease—new insights into dietary disease triggers
por: Logan, Michael, et al.
Publicado: (2020)

The Effects of Commonly Consumed Dietary Fibres on the Gut Microbiome and Its Fibre Fermentative Capacity in Adults with Inflammatory Bowel Disease in Remission
por: Gerasimidis, Konstantinos, et al.
Publicado: (2022)

Dietary triggers of gut inflammation following exclusive enteral nutrition in children with Crohn’s disease: a pilot study
por: Gkikas, Konstantinos, et al.
Publicado: (2021)

Development and Validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance
por: Jatkowska, Aleksandra, et al.
Publicado: (2023)

An Examination of Diet for the Maintenance of Remission in Inflammatory Bowel Disease
por: Haskey, Natasha, et al.
Publicado: (2017)

An automated identification and analysis of ontological terms in gastrointestinal diseases and nutrition-related literature provides useful insights
por: Koci, Orges, et al.
Publicado: (2018)

Point-of-care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic
por: Jere, Mwansa, et al.
Publicado: (2021)

Thromboprophylaxis for Hospitalized Patients with Inflammatory Bowel Disease—Are We There Yet?
por: Levartovsky, Asaf, et al.
Publicado: (2020)

Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment
por: Actis, Giovanni C, et al.
Publicado: (2017)

Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease
por: Logan, Michael, et al.
Publicado: (2022)

Association of sleep quality and mucosal healing in patients with inflammatory bowel disease in clinical remission
por: Michalopoulos, George, et al.
Publicado: (2018)

Novel Approaches in Addressing Ovarian Insufficiency in 2019: Are We There Yet?
por: Sfakianoudis, Konstantinos, et al.
Publicado: (2020)

The distinct features of microbial ‘dysbiosis’ of Crohn’s disease do not occur to the same extent in their unaffected, genetically-linked kindred
por: Ijaz, Umer Zeeshan, et al.
Publicado: (2017)

Inflammation associated ethanolamine facilitates infection by Crohn's disease-linked adherent-invasive Escherichia coli
por: Ormsby, Michael J., et al.
Publicado: (2019)

Are we there yet?
por: Wise, Jo Ann
Publicado: (2015)

Are we there yet?
por: Swann, Nicole
Publicado: (2019)

Are we there yet?
por: McCann, Shaun R.
Publicado: (2022)

Dietary treatment of Crohn’s disease: perceptions of families with children treated by exclusive enteral nutrition, a questionnaire survey
por: Svolos, Vaios, et al.
Publicado: (2017)

Pseudopolyps in inflammatory bowel diseases: Have we learned enough?
por: Politis, Dimitrios S, et al.
Publicado: (2017)

The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re‐introduction
por: Logan, Michael, et al.
Publicado: (2019)

Care of inflammatory bowel disease patients in remission
por: Raghu Subramanian, Charumathi, et al.
Publicado: (2016)

Are we nearly there yet?
por: Battersby, Stephen
Publicado: (2005)

Why Are We Not There Yet?
por: Wenger, Nanette K.
Publicado: (2021)

Patients with inflammatory bowel disease have higher abdominal adiposity and less skeletal mass than healthy controls
por: Barroso, Teresa, et al.
Publicado: (2018)

Alterations in Intestinal Microbiota of Children With Celiac Disease at the Time of Diagnosis and on a Gluten-free Diet
por: Zafeiropoulou, Konstantina, et al.
Publicado: (2020)

Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population
por: Principi, Mariabeatrice, et al.
Publicado: (2018)

Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Clinical Remission: What Should We Look For?
por: Stroie, Tudor, et al.
Publicado: (2022)

The effect of DNA extraction methodology on gut microbiota research applications
por: Gerasimidis, Konstantinos, et al.
Publicado: (2016)

Humanized mice: are we there yet?
por: Macchiarini, Francesca, et al.
Publicado: (2005)

Cancer vaccines: Are we there yet?
por: Hanna, Jr., Michael G.
Publicado: (2012)

Cancer immunotherapy: are we there yet?
por: Li, Zihai, et al.
Publicado: (2013)

Myocardial Inflammation—Are We There Yet?
por: Greulich, Simon, et al.
Publicado: (2015)

The Artificial Pancreas: Are We There Yet?
por: Cefalu, William T., et al.
Publicado: (2014)

Regenerative medicine: are we there yet?
por: Badylak, Stephen, et al.
Publicado: (2017)

Peak MSC—Are We There Yet?
por: Olsen, Timothy R., et al.
Publicado: (2018)

Dracunculiasis Eradication: Are We There Yet?
por: Hopkins, Donald R., et al.
Publicado: (2018)

Robotics and ophthalmology: Are we there yet?
por: Pandey, Suresh K, et al.
Publicado: (2019)

Precision Oncology: Are We There Yet?
Publicado: (2017)

Biomarkers for SUDEP: Are We There Yet?
por: King-Stephens, David
Publicado: (2019)

Safe Nanoparticles: Are We There Yet?
por: Najahi-Missaoui, Wided, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qb2j06dmun3jpif52de394uan5